Brandon Folkes analyst

Currently out of the existing stock ratings of Brandon Folkes, 227 are a BUY (92.28%), 19 are a HOLD (7.72%).

Brandon Folkes

Work Performance Price Targets & Ratings Chart

Analyst Brandon Folkes, has had 30.59% of price targets met with an average potential upside of 30.37%, reached in 234 days on average. Previously, Brandon Folkes worked at HC WAINWRIGHT.

Brandon Folkes has documented 484 price targets and ratings displayed on 50 stocks. The coverage was on Healthcare, Energy sectors.

Most recent stock forecast was given on OMER, Omeros.

Wall Street Analyst Brandon Folkes

Analyst best performing recommendations are on EGRX (EAGLE PHARMACEUTICALS).
The best stock recommendation documented was for EGRX (EAGLE PHARMACEUTICALS) on 11/7/2022. The price target of $37 was fulfilled within 1 day with a profit of $2.73 (6.87%), with a performance score of 68.71.

Average potential price target upside

BDSI BioDelivery Sciences International COLL Collegium Pharmaceutical EBS Emergent Biosolutions EGRX Eagle Pharmaceuticals HRTX Heron Therapeuti KIN Kindred Biosciences OPTN OptiNose TRVN Trevena VERU Veru ALKS Alkermes Plc JAZZ Jazz Pharmaceuticals PLC MNKD MannKind Corp IMV IMV OBSV ObsEva SA RDHL Redhill Biopharma Ltd OMER Omeros ACRX AcelRx Pharmaceuticals AMYT Amryt Pharma Holdings Ltd ANIP ANI Pharmaceuticals AXGN Axogen CERS Cerus CHMA Chiasma SPNE SeaSpine Holdings Corp VRAY ViewRay AZYO Aziyo Biologics RANI Rani Therapeutics Holdings RMTI Rockwell Medical SMTI Sanara Medtech ACHV Achieve Life Sciences AMAG AMAG Pharmaceuticals CRMD CorMedix DERM Journey Medical Corp INSY INSYS Therapeutics MNTA Momenta Pharmaceuticals PAHC Phibro Animal Health PYPD PolyPid TRVI Trevi Therapeutics VALN Valneva SE ADR CNTB Connect Biopharma Holdings Ltd ENTA Enanta Pharmaceuticals MIST Milestone Pharmaceuticals CRDL Cardiol Therapeutics XERS Xeris Pharmaceuticals ADIL Adial Pharmaceuticals AM Antero Midstream Partners LP GNFT Genfit INDV Indivior PLC SCLX Scilex Holding Company SGMT Sagimet Biosciences SINT SINTX Technologies

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Hold

$6

$8

4 years 8 months 24 days ago
(25-Feb-2022)

1/4 (25%)

$2.17 (44.83%)

281

Buy Since 09-Jan-2020

$5.6

$5.6

4 years 9 months 3 days ago
(15-Feb-2022)

2/3 (66.67%)

$0.04 (0.72%)

36

Hold Since 10-Nov-2021

$4.5

$4.5

4 years 9 months 28 days ago
(21-Jan-2022)

6/7 (85.71%)

$1.14 (33.93%)

152

Buy Since 14-Aug-2018

$6.25

$4.5

5 years 6 months 12 days ago
(06-May-2021)

2/3 (66.67%)

$3.07 (96.54%)

228

Buy Since 14-Oct-2015

$8

$21

7 years 5 days ago
(13-Nov-2019)

0/2 (0%)

$2 (33.33%)

Show more analysts

Please expand the browser size to see the chart

Which stock is Brandon Folkes most bullish on?

Potential upside of $18.78 has been obtained for SGMT (SAGIMET BIOSCIENCES)

Which stock is Brandon Folkes most reserved on?

Potential downside of $1.34 has been obtained for XERS (XERIS PHARMACEUTICALS)
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?